Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 22Gynecologic 4Genitourinary 4Breast 4Head & Neck 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Urothelial Cancer 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Metastatic Urothelial Cancer 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 8Sunitinib 7enfortumab vedotin 6Abiraterone Acetate 6enzalutamide 5Nivolumab 5Gemcitabine 5Cisplatin 5Carboplatin 4avelumab 3Prednisone 3Ipilimumab 3Docetaxel 3Androgen Antagonists 3sacituzumab govitecan 2olaparib 2niraparib 2erdafitinib 2entrectinib 2durvalumab 2darolutamide 2cabozantinib 2belzutifan 2apalutamide 2Pluvicto 2Mitomycin 2Leuprolide 2Everolimus 2Axitinib 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Carboplatin × Genitourinary × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡